Overall rank by patents
#28,450
Across all tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Chapman holds 9 US patents across 6 technology areas, rank #28,450 of 50,000 tracked assignees.
Chapman University has been granted 9 US utility patents between 2022 and 2025, placing Chapman University at rank #28,450 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Chapman University is one of the more focused assignees in the PatentsView dataset. By volume, Chapman sits between Central Adelaide Local Health Network Incorporated (9 patents, rank #28,446) and Cheetah Medical, Inc. (9 patents, rank #28,454) - the closest US assignees by grant volume. The composite Innovation Score of 44.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Chapman University's 13.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Chapman University against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Central Adelaide Local Health Network Incorporated
9 patents
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV)
9 patents
Certona Corporation
9 patents
Changsha Sinocare Inc.
9 patents
Charge Fusion Technologies, LLC
9 patents
Charles & Colvard, Ltd.
9 patents
Check Video LLC
9 patents
Cheetah Medical, Inc.
9 patents
Chapman University
9 patents
What this shows Chapman holds 9 patents at rank #28,450, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #28,450 in granted patent volume.
Other assignees with the most granted patents in Chapman's primary technology class.
Chapman's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 26% higher than 74% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 2 | 22.2% |
| 2023 | 2 | 22.2% |
| 2024 | 4 | 44.4% |
| 2025 | 1 | 11.1% |
Top 6 of 6 technology areas
Overall rank by patents
#28,450
Across all tracked assignees
44.4 out of 100
How to use this portfolio
Chapman's 9 grants land it in the top 26% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.